Respiratory Syncytial Virus

Abstract

Human respiratory syncytial virus (RSV) is a negative sense single-stranded RNA virus that can result in epidemics of seasonal respiratory infections. Generally, one of the two genotypes (A and B) predominates in a single season and alternate annually with regional variation. RSV is a known cause of disease and death at both extremes of ages in the pediatric and elderly, as well as immunocompromised populations. The clinical impact of RSV on the hospitalized adults has been recently clarified with the expanded use of multiplex molecular assays. Among adults, RSV can produce a wide range of clinical symptoms due to upper respiratory tract infections potentially leading to severe lower respiratory tract infections, as well as exacerbations of underlying cardiac and lung diseases. While supportive care is the mainstay of therapy, there are currently multiple therapeutic and preventative options under development.

Keywords

respiratory syncytial virus - ribavirin - palivizumab - presatovir - vaccine - pneumonia

Publication History

Article published online:
16 December 2021

• References

• 1 Nair H, Nokes DJ, Gessner BD. et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet 2010; 375 (9725): 1545-1555
• 2 Falsey AR, Hennessey PA, Formica MA, Cox C, Walsh EE. Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med 2005; 352 (17) 1749-1759
• 3 Jansen AG, Sanders EA, Hoes AW, van Loon AM, Hak E. Influenza- and respiratory syncytial virus-associated mortality and hospitalisations. Eur Respir J 2007; 30 (06) 1158-1166
• 4 Nam HH, Ison MG. Respiratory syncytial virus infection in adults. BMJ 2019; 366: l5021
• 5 Chanock R, Finberg L. Recovery from infants with respiratory illness of a virus related to chimpanzee coryza agent (CCA). II. Epidemiologic aspects of infection in infants and young children. Am J Hyg 1957; 66 (03) 291-300
• 6 Afonso CL, Amarasinghe GK, Bányai K. et al. Taxonomy of the order Mononegavirales: update 2016. Arch Virol 2016; 161 (08) 2351-2360
• 7 Rima B, Collins P, Easton A. et al; Ictv Report Consortium. ICTV virus taxonomy profile: Pneumoviridae. J Gen Virol 2017; 98 (12) 2912-2913
• 8 Glezen WP, Taber LH, Frank AL, Kasel JA. Risk of primary infection and reinfection with respiratory syncytial virus. Am J Dis Child 1986; 140 (06) 543-546
• 9 Taleb SA, Al Thani AA, Al Ansari K, Yassine HM. Human respiratory syncytial virus: pathogenesis, immune responses, and current vaccine approaches. Eur J Clin Microbiol Infect Dis 2018; 37 (10) 1817-1827
• 10 Gan SW, Ng L, Lin X, Gong X, Torres J. Structure and ion channel activity of the human respiratory syncytial virus (hRSV) small hydrophobic protein transmembrane domain. Protein Sci 2008; 17 (05) 813-820
• 11 Walsh EE. Respiratory syncytial virus infection: an illness for all ages. Clin Chest Med 2017; 38 (01) 29-36
• 12 Colman PM, Lawrence MC. The structural biology of type I viral membrane fusion. Nat Rev Mol Cell Biol 2003; 4 (04) 309-319
• 13 Krzyzaniak MA, Zumstein MT, Gerez JA, Picotti P, Helenius A. Host cell entry of respiratory syncytial virus involves macropinocytosis followed by proteolytic activation of the F protein. PLoS Pathog 2013; 9 (04) e1003309
• 14 McLellan JS, Ray WC, Peeples ME. Structure and function of respiratory syncytial virus surface glycoproteins. Curr Top Microbiol Immunol 2013; 372: 83-104
• 15 Vekemans J, Moorthy V, Giersing B. et al. Respiratory syncytial virus vaccine research and development: World Health Organization technological roadmap and preferred product characteristics. Vaccine 2019; 37 (50) 7394-7395
• 16 Cullen LM, Schmidt MR, Morrison TG. The importance of RSV F protein conformation in VLPs in stimulation of neutralizing antibody titers in mice previously infected with RSV. Hum Vaccin Immunother 2017; 13 (12) 2814-2823
• 17 Anderson LJ, Hierholzer JC, Tsou C. et al. Antigenic characterization of respiratory syncytial virus strains with monoclonal antibodies. J Infect Dis 1985; 151 (04) 626-633
• 18 Pangesti KNA, Abd El Ghany M, Walsh MG, Kesson AM, Hill-Cawthorne GA. Molecular epidemiology of respiratory syncytial virus. Rev Med Virol 2018; 28 (02) 28
• 19 Schmidt H, Das A, Nam H, Yang A, Ison MG. Epidemiology and outcomes of hospitalized adults with respiratory syncytial virus: a 6-year retrospective study. Influenza Other Respir Viruses 2019; 13 (04) 331-338
• 20 Hall CB, Douglas Jr RG. Modes of transmission of respiratory syncytial virus. J Pediatr 1981; 99 (01) 100-103
• 21 Hall CB. Nosocomial respiratory syncytial virus infections: the “Cold War” has not ended. Clin Infect Dis 2000; 31 (02) 590-596
• 22 French CE, McKenzie BC, Coope C. et al; Noso-RSV Study Group. Risk of nosocomial respiratory syncytial virus infection and effectiveness of control measures to prevent transmission events: a systematic review. Influenza Other Respir Viruses 2016; 10 (04) 268-290
• 23 Siegel JD, Rhinehart E, Jackson M. et al. 2007 Guideline for isolation precautions: preventing transmission of infectious agents in healthcare settings. Update May 2019. Accessed September 9, 2021 at: https://www.cdc.gov/infectioncontrol/pdf/guidelines/isolation-guidelines-H.pdf
• 24 Agah R, Cherry JD, Garakian AJ, Chapin M. Respiratory syncytial virus (RSV) infection rate in personnel caring for children with RSV infections. Routine isolation procedure vs routine procedure supplemented by use of masks and goggles. Am J Dis Child 1987; 141 (06) 695-697
• 25 Sokol KA, De la Vega-Diaz I, Edmondson-Martin K. et al. Masks for prevention of respiratory viruses on the BMT unit: results of a quality initiative. Transpl Infect Dis 2016; 18 (06) 965-967
• 26 Sung AD, Sung JAM, Thomas S. et al. Universal mask usage for reduction of respiratory viral infections after stem cell transplant: a prospective trial. Clin Infect Dis 2016; 63 (08) 999-1006
• 27 Fox B, Barkley E, Rasmussen D, Teriakidis A. RSV cases dropped by 97% during the pandemic. Epic Health Research Network. 2021. Accessed September 9, 2021 at: https://ehrn.org/articles/rsv-cases-dropped-by-97-during-the-pandemic#:∼:text=Abstract%3A%20The%20number%20of%20positive,rates%20in%20some%20age%20groups
• 28 Kassis C, Champlin RE, Hachem RY. et al. Detection and control of a nosocomial respiratory syncytial virus outbreak in a stem cell transplantation unit: the role of palivizumab. Biol Blood Marrow Transplant 2010; 16 (09) 1265-1271
• 29 Zhang L, Peeples ME, Boucher RC, Collins PL, Pickles RJ. Respiratory syncytial virus infection of human airway epithelial cells is polarized, specific to ciliated cells, and without obvious cytopathology. J Virol 2002; 76 (11) 5654-5666
• 30 Damasio GA, Pereira LA, Moreira SD, Duarte dos Santos CN, Dalla-Costa LM, Raboni SM. Does virus-bacteria coinfection increase the clinical severity of acute respiratory infection?. J Med Virol 2015; 87 (09) 1456-1461
• 31 McNamara PS, Ritson P, Selby A, Hart CA, Smyth RL. Bronchoalveolar lavage cellularity in infants with severe respiratory syncytial virus bronchiolitis. Arch Dis Child 2003; 88 (10) 922-926
• 32 Garcia-Mauriño C, Moore-Clingenpeel M, Thomas J. et al. Viral load dynamics and clinical disease severity in infants with respiratory syncytial virus infection. J Infect Dis 2019; 219 (08) 1207-1215
• 33 Griffiths C, Drews SJ, Marchant DJ. Respiratory syncytial virus: infection, detection, and new options for prevention and treatment. Clin Microbiol Rev 2017; 30 (01) 277-319
• 34 Graham BS. Vaccine development for respiratory syncytial virus. Curr Opin Virol 2017; 23: 107-112
• 35 Habibi MS, Jozwik A, Makris S. et al; Mechanisms of Severe Acute Influenza Consortium Investigators. Impaired antibody-mediated protection and defective IgA B-cell memory in experimental infection of adults with respiratory syncytial virus. Am J Respir Crit Care Med 2015; 191 (09) 1040-1049
• 36 Brandenburg AH, Groen J, van Steensel-Moll HA. et al. Respiratory syncytial virus specific serum antibodies in infants under six months of age: limited serological response upon infection. J Med Virol 1997; 52 (01) 97-104
• 37 Murphy BR, Graham BS, Prince GA. et al. Serum and nasal-wash immunoglobulin G and A antibody response of infants and children to respiratory syncytial virus F and G glycoproteins following primary infection. J Clin Microbiol 1986; 23 (06) 1009-1014
• 38 Falsey AR, Singh HK, Walsh EE. Serum antibody decay in adults following natural respiratory syncytial virus infection. J Med Virol 2006; 78 (11) 1493-1497
• 39 Tripp RA, Power UF, Openshaw PJM, Kauvar LM. Respiratory syncytial virus: targeting the G protein provides a new approach for an old problem. J Virol 2018; 92 (03) 17
• 40 Schmidt MR, McGinnes-Cullen LW, Kenward SA, Willems KN, Woodland RT, Morrison TG. Modification of the respiratory syncytial virus f protein in virus-like particles impacts generation of B cell memory. J Virol 2014; 88 (17) 10165-10176
• 41 Van Der Plas JL, Verdijk P, Van Brummelen EMJ. et al. Prevalent levels of RSV serum neutralizing antibodies in healthy adults outside the RSV-season. Hum Vaccin Immunother 2020; 16 (06) 1322-1326
• 42 Welliver TP, Reed JL, Welliver Sr RC. Respiratory syncytial virus and influenza virus infections: observations from tissues of fatal infant cases. Pediatr Infect Dis J 2008; 27 (10, Suppl): S92-S96
• 43 Hegele RG, Hayashi S, Hogg JC, Paré PD. Mechanisms of airway narrowing and hyperresponsiveness in viral respiratory tract infections. Am J Respir Crit Care Med 1995; 151 (05) 1659-1664 , discussion 1664–1665
• 44 Branche AR, Falsey AR. Respiratory syncytial virus infection in older adults: an under-recognized problem. Drugs Aging 2015; 32 (04) 261-269
• 45 Lieberman D, Shimoni A, Shemer-Avni Y, Keren-Naos A, Shtainberg R, Lieberman D. Respiratory viruses in adults with community-acquired pneumonia. Chest 2010; 138 (04) 811-816
• 46 Chartrand C, Tremblay N, Renaud C, Papenburg J. Diagnostic accuracy of rapid antigen detection tests for respiratory syncytial virus infection: systematic review and meta-analysis. J Clin Microbiol 2015; 53 (12) 3738-3749
• 47 Casiano-Colón AE, Hulbert BB, Mayer TK, Walsh EE, Falsey AR. Lack of sensitivity of rapid antigen tests for the diagnosis of respiratory syncytial virus infection in adults. J Clin Virol 2003; 28 (02) 169-174
• 48 Schwartz RH, Selvarangan R, Zissman EN. BD veritor system respiratory syncytial virus rapid antigen detection test: point-of-care results in primary care pediatric offices compared with reverse transcriptase polymerase chain reaction and viral culture methods. Pediatr Emerg Care 2015; 31 (12) 830-834
• 49 Talbot HK, Falsey AR. The diagnosis of viral respiratory disease in older adults. Clin Infect Dis 2010; 50 (05) 747-751
• 50 Falsey AR, Formica MA, Walsh EE. Diagnosis of respiratory syncytial virus infection: comparison of reverse transcription-PCR to viral culture and serology in adults with respiratory illness. J Clin Microbiol 2002; 40 (03) 817-820
• 51 Bashir U, Alam MM, Sadia H, Zaidi SS, Kazi BM. Molecular characterization of circulating respiratory syncytial virus (RSV) genotypes in Gilgit Baltistan Province of Pakistan during 2011-2012 winter season. PLoS One 2013; 8 (09) e74018
• 52 Al-Toum R, Bdour S, Ayyash H. Epidemiology and clinical characteristics of respiratory syncytial virus infections in Jordan. J Trop Pediatr 2006; 52 (04) 282-287
• 53 DeVincenzo JP, McClure MW, Symons JA. et al. Activity of oral ALS-008176 in a respiratory syncytial virus challenge study. N Engl J Med 2015; 373 (21) 2048-2058
• 54 Martinello RA, Chen MD, Weibel C, Kahn JS. Correlation between respiratory syncytial virus genotype and severity of illness. J Infect Dis 2002; 186 (06) 839-842
• 55 Espinosa Y, San Martín C, Torres AA. et al. Genomic loads and genotypes of respiratory syncytial virus: viral factors during lower respiratory tract infection in chilean hospitalized infants. Int J Mol Sci 2017; 18 (03) 654
• 56 Binder W, Thorsen J, Borczuk P. RSV in adult ED patients: Do emergency providers consider RSV as an admission diagnosis?. Am J Emerg Med 2017; 35 (08) 1162-1165
• 57 Korsten K, Adriaenssens N, Coenen S. et al; RESCEU investigators. Burden of respiratory syncytial virus infection in community-dwelling older adults in Europe (RESCEU): an international prospective cohort study. Eur Respir J 2021; 57 (04) 57
• 58 Colosia AD, Yang J, Hillson E. et al. The epidemiology of medically attended respiratory syncytial virus in older adults in the United States: a systematic review. PLoS One 2017; 12 (08) e0182321
• 59 Hall CB. Respiratory syncytial virus and parainfluenza virus. N Engl J Med 2001; 344 (25) 1917-1928
• 60 Thompson WW, Shay DK, Weintraub E. et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 2003; 289 (02) 179-186
• 61 Jain S, Self WH, Wunderink RG. et al; CDC EPIC Study Team. Community-acquired pneumonia requiring hospitalization among U.S. adults. N Engl J Med 2015; 373 (05) 415-427
• 62 Branche AR, Saiman L, Walsh EE. et al. Incidence of respiratory syncytial virus infection among hospitalized adults, 2017-2020. Clin Infect Dis 2021; (e-pub ahead of print)
• 63 Widmer K, Griffin MR, Zhu Y, Williams JV, Talbot HK. Respiratory syncytial virus- and human metapneumovirus-associated emergency department and hospital burden in adults. Influenza Other Respir Viruses 2014; 8 (03) 347-352
• 64 Falsey AR, McElhaney JE, Beran J. et al. Respiratory syncytial virus and other respiratory viral infections in older adults with moderate to severe influenza-like illness. J Infect Dis 2014; 209 (12) 1873-1881
• 65 Beckhaus AA, Castro-Rodriguez JA. Down syndrome and the risk of severe RSV Infection: a meta-analysis. Pediatrics 2018; 142 (03) 142
• 66 Chatzis O, Darbre S, Pasquier J. et al. Burden of severe RSV disease among immunocompromised children and adults: a 10 year retrospective study. BMC Infect Dis 2018; 18 (01) 111
• 67 Choudhuri JA, Ogden LG, Ruttenber AJ, Thomas DS, Todd JK, Simoes EA. Effect of altitude on hospitalizations for respiratory syncytial virus infection. Pediatrics 2006; 117 (02) 349-356
• 68 Ivey KS, Edwards KM, Talbot HK. Respiratory syncytial virus and associations with cardiovascular disease in adults. J Am Coll Cardiol 2018; 71 (14) 1574-1583
• 69 Weinberg A, Lyu DM, Li S, Marquesen J, Zamora MR. Incidence and morbidity of human metapneumovirus and other community-acquired respiratory viruses in lung transplant recipients. Transpl Infect Dis 2010; 12 (04) 330-335
• 70 Milstone AP, Brumble LM, Barnes J. et al. A single-season prospective study of respiratory viral infections in lung transplant recipients. Eur Respir J 2006; 28 (01) 131-137
• 71 Wald TG, Miller BA, Shult P. et al. Can respiratory syncytial virus and influenza A be distinguished clinically in institutionalized older persons?. J Am Geriatr Soc 1995; 43 (02) 170-174
• 72 Falsey AR, Criddle MC, Walsh EE. Detection of respiratory syncytial virus and human metapneumovirus by reverse transcription polymerase chain reaction in adults with and without respiratory illness. J Clin Virol 2006; 35 (01) 46-50
• 73 Self WH, Williams DJ, Zhu Y. et al. Respiratory viral detection in children and adults: comparing asymptomatic controls and patients with community-acquired pneumonia. J Infect Dis 2016; 213 (04) 584-591
• 74 Falsey AR, Walsh EE. Respiratory syncytial virus infection in adults. Clin Microbiol Rev 2000; 13 (03) 371-384
• 75 Sundaram ME, Meece JK, Sifakis F, Gasser Jr RA, Belongia EA. Medically attended respiratory syncytial virus infections in adults aged ≥ 50 years: clinical characteristics and outcomes. Clin Infect Dis 2014; 58 (03) 342-349
• 76 Walsh EE, Peterson DR, Falsey AR. Is clinical recognition of respiratory syncytial virus infection in hospitalized elderly and high-risk adults possible?. J Infect Dis 2007; 195 (07) 1046-1051
• 77 Ariza-Heredia EJ, Fishman JE, Cleary T, Smith L, Razonable RR, Abbo L. Clinical and radiological features of respiratory syncytial virus in solid organ transplant recipients: a single-center experience. Transpl Infect Dis 2012; 14 (01) 64-71
• 78 Schiffer JT, Kirby K, Sandmaier B, Storb R, Corey L, Boeckh M. Timing and severity of community acquired respiratory virus infections after myeloablative versus non-myeloablative hematopoietic stem cell transplantation. Haematologica 2009; 94 (08) 1101-1108
• 79 Boeckh M, Englund J, Li Y. et al; NIAID Collaborative Antiviral Study Group. Randomized controlled multicenter trial of aerosolized ribavirin for respiratory syncytial virus upper respiratory tract infection in hematopoietic cell transplant recipients. Clin Infect Dis 2007; 44 (02) 245-249
• 80 Kim YJ, Guthrie KA, Waghmare A. et al. Respiratory syncytial virus in hematopoietic cell transplant recipients: factors determining progression to lower respiratory tract disease. J Infect Dis 2014; 209 (08) 1195-1204
• 81 Lee N, Lui GC, Wong KT. et al. High morbidity and mortality in adults hospitalized for respiratory syncytial virus infections. Clin Infect Dis 2013; 57 (08) 1069-1077
• 82 Timbrook T, Maxam M, Bosso J. Antibiotic discontinuation rates associated with positive respiratory viral panel and low procalcitonin results in proven or suspected respiratory infections. Infect Dis Ther 2015; 4 (03) 297-306
• 83 Cohen R, Babushkin F, Geller K, Finn T. Characteristics of hospitalized adult patients with laboratory documented Influenza A, B and respiratory syncytial virus - a single center retrospective observational study. PLoS One 2019; 14 (03) e0214517
• 84 Shi T, Denouel A, Tietjen AK. et al. RESCEU Investigators.. Global disease burden estimates of respiratory syncytial virus–associated acute respiratory infection in older adults in 2015: a systematic review and meta-analysis. J Infect Dis 2020; 222 (Suppl. 07) S577-S583
• 85 Woodhead M, Blasi F, Ewig S. et al; Joint Taskforce of the European Respiratory Society and European Society for Clinical Microbiology and Infectious Diseases. Guidelines for the management of adult lower respiratory tract infections–full version. Clin Microbiol Infect 2011; 17 (Suppl. 06) E1-E59
• 86 Mehta J, Walsh EE, Mahadevia PJ, Falsey AR. Risk factors for respiratory syncytial virus illness among patients with chronic obstructive pulmonary disease. COPD 2013; 10 (03) 293-299
• 87 Loubet P, Lenzi N, Valette M. et al; FLUVAC Study Group. Clinical characteristics and outcome of respiratory syncytial virus infection among adults hospitalized with influenza-like illness in France. Clin Microbiol Infect 2017; 23 (04) 253-259
• 88 Volling C, Hassan K, Mazzulli T. et al. Respiratory syncytial virus infection-associated hospitalization in adults: a retrospective cohort study. BMC Infect Dis 2014; 14: 665
• 89 Falsey AR, Cunningham CK, Barker WH. et al. Respiratory syncytial virus and influenza A infections in the hospitalized elderly. J Infect Dis 1995; 172 (02) 389-394
• 90 Fishaut M, Tubergen D, McIntosh K. Cellular response to respiratory viruses with particular reference to children with disorders of cell-mediated immunity. J Pediatr 1980; 96 (02) 179-186
• 91 Manuel O, Estabrook M. American Society of Transplantation Infectious Diseases Community of Practice. RNA respiratory viral infections in solid organ transplant recipients: guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant 2019; 33 (09) e13511
• 92 Chemaly RF, Shah DP, Boeckh MJ. Management of respiratory viral infections in hematopoietic cell transplant recipients and patients with hematologic malignancies. Clin Infect Dis 2014; 59 (Suppl. 05) S344-S351
• 93 Waghmare A, Campbell AP, Xie H. et al. Respiratory syncytial virus lower respiratory disease in hematopoietic cell transplant recipients: viral RNA detection in blood, antiviral treatment, and clinical outcomes. Clin Infect Dis 2013; 57 (12) 1731-1741
• 94 Chemaly RF, Ghosh S, Bodey GP. et al. Respiratory viral infections in adults with hematologic malignancies and human stem cell transplantation recipients: a retrospective study at a major cancer center. Medicine (Baltimore) 2006; 85 (05) 278-287
• 95 Ljungman P. Respiratory syncytial virus in hematopoietic cell transplant recipients: factors determining progression to lower respiratory tract disease. J Infect Dis 2014; 209 (08) 1151-1152
• 96 Shah JN, Chemaly RF. Management of RSV infections in adult recipients of hematopoietic stem cell transplantation. Blood 2011; 117 (10) 2755-2763
• 97 Khanna N, Widmer AF, Decker M. et al. Respiratory syncytial virus infection in patients with hematological diseases: single-center study and review of the literature. Clin Infect Dis 2008; 46 (03) 402-412
• 98 Shah DP, Ghantoji SS, Ariza-Heredia EJ. et al. Immunodeficiency scoring index to predict poor outcomes in hematopoietic cell transplant recipients with RSV infections. Blood 2014; 123 (21) 3263-3268
• 99 Weigt SS, Gregson AL, Deng JC, Lynch III JP, Belperio JA. Respiratory viral infections in hematopoietic stem cell and solid organ transplant recipients. Semin Respir Crit Care Med 2011; 32 (04) 471-493
• 100 López-Medrano F, Aguado JM, Lizasoain M. et al. Clinical implications of respiratory virus infections in solid organ transplant recipients: a prospective study. Transplantation 2007; 84 (07) 851-856
• 101 Belperio JA, Weigt SS, Fishbein MC, Lynch III JP. Chronic lung allograft rejection: mechanisms and therapy. Proc Am Thorac Soc 2009; 6 (01) 108-121
• 102 Mandell LA, Wunderink RG, Anzueto A. et al; Infectious Diseases Society of America, American Thoracic Society. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44 (Suppl. 02) S27-S72
• 103 Metlay JP, Waterer GW, Long AC. et al. Diagnosis and treatment of adults with community-acquired pneumonia. an official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med 2019; 200 (07) e45-e67
• 104 Woodhead M, Blasi F, Ewig S. et al; European Respiratory Society, European Society of Clinical Microbiology and Infectious Diseases. Guidelines for the management of adult lower respiratory tract infections. Eur Respir J 2005; 26 (06) 1138-1180
• 105 Hirsch HH, Martino R, Ward KN, Boeckh M, Einsele H, Ljungman P. Fourth European Conference on Infections in Leukaemia (ECIL-4): Guidelines for diagnosis and treatment of human respiratory syncytial virus, parainfluenza virus, metapneumovirus, rhinovirus, and coronavirus. Clin Infect Dis 2013; 56 (02) 258-266
• 106 Zaia J, Baden L, Boeckh MJ. et al; Center for International Blood and Marrow Transplant Research, National Marrow Donor Program, European Blood and Marrow Transplant Group, American Society of Blood and Marrow Transplantation, Canadian Blood and Marrow Transplant Group, Infectious Disease Society of America, Society for Healthcare Epidemiology of America, Association of Medical Microbiology and Infectious Diseases Canada, Centers for Disease Control and Prevention. Viral disease prevention after hematopoietic cell transplantation. Bone Marrow Transplant 2009; 44 (08) 471-482
• 107 Broadbent L, Groves H, Shields MD, Power UF. Respiratory syncytial virus, an ongoing medical dilemma: an expert commentary on respiratory syncytial virus prophylactic and therapeutic pharmaceuticals currently in clinical trials. Influenza Other Respir Viruses 2015; 9 (04) 169-178
• 108 Hall CB, Walsh EE, Hruska JF, Betts RF, Hall WJ. Ribavirin treatment of experimental respiratory syncytial viral infection. A controlled double-blind study in young adults. JAMA 1983; 249 (19) 2666-2670
• 109 Taber LH, Knight V, Gilbert BE. et al. Ribavirin aerosol treatment of bronchiolitis associated with respiratory syncytial virus infection in infants. Pediatrics 1983; 72 (05) 613-618
• 110 Randolph AG, Wang EE. Ribavirin for respiratory syncytial virus lower respiratory tract infection. A systematic overview. Arch Pediatr Adolesc Med 1996; 150 (09) 942-947
• 111 Beaird OE, Freifeld A, Ison MG. et al. Current practices for treatment of respiratory syncytial virus and other non-influenza respiratory viruses in high-risk patient populations: a survey of institutions in the Midwestern Respiratory Virus Collaborative. Transpl Infect Dis 2016; 18 (02) 210-215
• 112 Chemaly RF, Aitken SL, Wolfe CR, Jain R, Boeckh MJ. Aerosolized ribavirin: the most expensive drug for pneumonia. Transpl Infect Dis 2016; 18 (04) 634-636
• 113 Trang TP, Whalen M, Hilts-Horeczko A, Doernberg SB, Liu C. Comparative effectiveness of aerosolized versus oral ribavirin for the treatment of respiratory syncytial virus infections: a single-center retrospective cohort study and review of the literature. Transpl Infect Dis 2018; 20 (02) e12844
• 114 Ghosh S, Champlin RE, Englund J. et al. Respiratory syncytial virus upper respiratory tract illnesses in adult blood and marrow transplant recipients: combination therapy with aerosolized ribavirin and intravenous immunoglobulin. Bone Marrow Transplant 2000; 25 (07) 751-755
• 115 McCarthy AJ, Kingman HM, Kelly C. et al. The outcome of 26 patients with respiratory syncytial virus infection following allogeneic stem cell transplantation. Bone Marrow Transplant 1999; 24 (12) 1315-1322
• 116 Lewinsohn DM, Bowden RA, Mattson D, Crawford SW. Phase I study of intravenous ribavirin treatment of respiratory syncytial virus pneumonia after marrow transplantation. Antimicrob Agents Chemother 1996; 40 (11) 2555-2557
• 117 Nichols WG, Gooley T, Boeckh M. Community-acquired respiratory syncytial virus and parainfluenza virus infections after hematopoietic stem cell transplantation: the Fred Hutchinson Cancer Research Center experience. Biol Blood Marrow Transplant 2001; 7 (Suppl): 11S-15S
• 118 Chemaly RF, Dadwal SS, Bergeron A. et al. A phase 2, randomized, double-blind, placebo-controlled trial of presatovir for the treatment of respiratory syncytial virus upper respiratory tract infection in hematopoietic-cell transplant recipients. Clin Infect Dis 2020; 71 (11) 2777-2786
• 119 Gottlieb J, Torres F, Haddad T. et al. A phase 2b randomized controlled trial of presatovir, an oral RSV fusion inhibitor, for the treatment of respiratory syncytial virus (RSV) in lung transplant (LT) recipients. J Heart Lung Transplant 2018; 37: S155
• 120 Marty FM, Chemaly RF, Mullane KM. et al. A phase 2b, randomized, double-blind, placebo-controlled multicenter study evaluating antiviral effects, pharmacokinetics, safety, and tolerability of presatovir in hematopoietic cell transplant recipients with respiratory syncytial virus infection of the lower respiratory tract. Clin Infect Dis 2020; 71 (11) 2787-2795
• 121 Foolad F, Aitken SL, Shigle TL. et al. Oral versus aerosolized ribavirin for the treatment of respiratory syncytial virus infections in hematopoietic cell transplantation recipients. Clin Infect Dis 2019; 68 (10) 1641-1649
• 122 Marcelin JR, Wilson JW, Razonable RR. Mayo Clinic Hematology/Oncology and Transplant Infectious Diseases Services. Oral ribavirin therapy for respiratory syncytial virus infections in moderately to severely immunocompromised patients. Transpl Infect Dis 2014; 16 (02) 242-250
• 123 Chávez-Bueno S, Mejías A, Merryman RA, Ahmad N, Jafri HS, Ramilo O. Intravenous palivizumab and ribavirin combination for respiratory syncytial virus disease in high-risk pediatric patients. Pediatr Infect Dis J 2007; 26 (12) 1089-1093
• 124 Seo S, Campbell AP, Xie H. et al. Outcome of respiratory syncytial virus lower respiratory tract disease in hematopoietic cell transplant recipients receiving aerosolized ribavirin: significance of stem cell source and oxygen requirement. Biol Blood Marrow Transplant 2013; 19 (04) 589-596
• 125 Domachowske JB, Anderson EJ, Goldstein M. The future of respiratory syncytial virus disease prevention and treatment. Infect Dis Ther 2021; 10 (Suppl. 01) 47-60
• 126 American Academy of Pediatrics Committee on Infectious Diseases, American Academy of Pediatrics Bronchiolitis Guidelines Committee. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics 2014; 134 (02) 415-420
• 127 Shadman KA, Wald ER. A review of palivizumab and emerging therapies for respiratory syncytial virus. Expert Opin Biol Ther 2011; 11 (11) 1455-1467
• 128 de Fontbrune FS, Robin M, Porcher R. et al. Palivizumab treatment of respiratory syncytial virus infection after allogeneic hematopoietic stem cell transplantation. Clin Infect Dis 2007; 45 (08) 1019-1024
• 129 Liu V, Dhillon GS, Weill D. A multi-drug regimen for respiratory syncytial virus and parainfluenza virus infections in adult lung and heart-lung transplant recipients. Transpl Infect Dis 2010; 12 (01) 38-44
• 130 Domachowske JB, Khan AA, Esser MT. et al. Safety, tolerability and pharmacokinetics of MEDI8897, an extended half-life single-dose respiratory syncytial virus prefusion F-targeting monoclonal antibody administered as a single dose to healthy preterm infants. Pediatr Infect Dis J 2018; 37 (09) 886-892
• 131 Kim HW, Canchola JG, Brandt CD. et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol 1969; 89 (04) 422-434
• 132 Healy CM. Vaccines in pregnant women and research initiatives. Clin Obstet Gynecol 2012; 55 (02) 474-486
• 133 Graham BS, Modjarrad K, McLellan JS. Novel antigens for RSV vaccines. Curr Opin Immunol 2015; 35: 30-38
• 134 Knudson CJ, Hartwig SM, Meyerholz DK, Varga SM. RSV vaccine-enhanced disease is orchestrated by the combined actions of distinct CD4 T cell subsets. PLoS Pathog 2015; 11 (03) e1004757
• 135 Liang B, Ngwuta JO, Herbert R. et al. Packaging and prefusion stabilization separately and additively increase the quantity and quality of respiratory syncytial virus (RSV)-neutralizing antibodies induced by an RSV fusion protein expressed by a parainfluenza virus vector. J Virol 2016; 90 (21) 10022-10038
• 136 Johnson TR, Rangel D, Graham BS, Brough DE, Gall JG. Genetic vaccine for respiratory syncytial virus provides protection without disease potentiation. Mol Ther 2014; 22 (01) 196-205
• 137 Taylor G, Thom M, Capone S. et al. Efficacy of a virus-vectored vaccine against human and bovine respiratory syncytial virus infections. Sci Transl Med 2015; 7 (300) 300ra127
• 138 Widjojoatmodjo MN, Bogaert L, Meek B. et al. Recombinant low-seroprevalent adenoviral vectors Ad26 and Ad35 expressing the respiratory syncytial virus (RSV) fusion protein induce protective immunity against RSV infection in cotton rats. Vaccine 2015; 33 (41) 5406-5414
• 139 Geall AJ, Verma A, Otten GR. et al. Nonviral delivery of self-amplifying RNA vaccines. Proc Natl Acad Sci U S A 2012; 109 (36) 14604-14609
• 140 Gilman MS, Castellanos CA, Chen M. et al. Rapid profiling of RSV antibody repertoires from the memory B cells of naturally infected adult donors. Sci Immunol 2016; 1 (06) 1
• 141 Amirthalingam G, Andrews N, Campbell H. et al. Effectiveness of maternal pertussis vaccination in England: an observational study. Lancet 2014; 384 (9953): 1521-1528
• 142 Zaman K, Roy E, Arifeen SE. et al. Effectiveness of maternal influenza immunization in mothers and infants. N Engl J Med 2008; 359 (15) 1555-1564
• 143 Chu HY, Steinhoff MC, Magaret A. et al. Respiratory syncytial virus transplacental antibody transfer and kinetics in mother-infant pairs in Bangladesh. J Infect Dis 2014; 210 (10) 1582-1589
• 144 Munoz FM, Piedra PA, Vaccine G-WP. Safety and immunogenicity of respiratory syncytial virus purified fusion protein-2 vaccine in pregnant women. Vaccine 2003; 21 (24) 3465-3467
• 145 Roberts JN, Graham BS, Karron RA. et al. Challenges and opportunities in RSV vaccine development: meeting report from FDA/NIH workshop. Vaccine 2016; 34 (41) 4843-4849
• 146 Cho CH, Lee CK, Nam M-H. et al. Evaluation of the AdvanSure™ real-time RT-PCR compared with culture and Seeplex RV15 for simultaneous detection of respiratory viruses. Diagn Microbiol Infect Dis 2014; 79 (01) 14-18
• 147 Liao RS, Tomalty LL, Majury A, Zoutman DE. Comparison of viral isolation and multiplex real-time reverse transcription-PCR for confirmation of respiratory syncytial virus and influenza virus detection by antigen immunoassays. J Clin Microbiol 2009; 47 (03) 527-532
• 148 Popow-Kraupp T, Aberle JH. Diagnosis of respiratory syncytial virus infection. Open Microbiol J 2011; 5: 128-134
• 149 Salez N, Nougairede A, Ninove L, Zandotti C, de Lamballerie X, Charrel RN. Prospective and retrospective evaluation of the Cepheid Xpert® Flu/RSV XC assay for rapid detection of influenza A, influenza B, and respiratory syncytial virus. Diagn Microbiol Infect Dis 2015; 81 (04) 256-258
• 150 Popowitch EB, Miller MB. Performance characteristics of Xpert Flu/RSV XC assay. J Clin Microbiol 2015; 53 (08) 2720-2721
• 151 Gharabaghi F, Hawan A, Drews SJ, Richardson SE. Evaluation of multiple commercial molecular and conventional diagnostic assays for the detection of respiratory viruses in children. Clin Microbiol Infect 2011; 17 (12) 1900-1906
• 152 Gadsby NJ, Hardie A, Claas ECJ, Templeton KE. Comparison of the Luminex Respiratory Virus Panel fast assay with in-house real-time PCR for respiratory viral infection diagnosis. J Clin Microbiol 2010; 48 (06) 2213-2216
• 153 Landry ML, Ferguson D. Comparison of Simplexa Flu A/B & RSV PCR with cytospin-immunofluorescence and laboratory-developed TaqMan PCR in predominantly adult hospitalized patients. J Clin Microbiol 2014; 52 (08) 3057-3059